VolitionRX Receives a Buy from H.C. Wainwright

By Ryan Adsit

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on VolitionRX (NYSE: VNRX) yesterday and set a price target of $10. The company’s shares closed yesterday at $4.55.

Selvaraju observed:

“We expect the study to complete in approximately two months. The company may conduct similar logistical studies in other EU countries where it plans to launch Nu.Q™, in our view. We currently expect the company to start recognizing sales of Nu.Q™ in 2H 2017.”

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -2.7% and a 37.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as RegeneRx Biopharmaceuticals Inc, Biospecifics Technologies Corp, and HTG Molecular Diagnostics.

VolitionRX has an analyst consensus of Moderate Buy.

Based on VolitionRX’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $0 and GAAP net loss of $2.98 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $2.69 million.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VNRX in relation to earlier this year. Most recently, in June 2016, Guy Archibald Innes, a Director at VNRX bought 5,484 shares for a total of $2,742.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VolitionRX Ltd. operates clinical-stage life sciences company, which focuses on developing blood-based diagnostic tests that meet the need for accurate, fast, inexpensive and scalable tests for detecting and diagnosing cancer and other diseases. The company was founded on August 5, 2010 and is headquartered in Singapore.